Aptevo Therapeutics enters $25M standby equity purchase agreement with Yorkville

Aptevo Therapeutics Inc.

Up to $25M in common stock may be sold to YA II PN over 36 months at 96% of lowest 3-day VWAP.
Exchange cap of 151,755 shares (19.99% of outstanding) unless stockholder approval or avg price ≥ $3.66.
Yorkville's beneficial ownership limited to 9.99% of outstanding shares.
Structuring fee of $25,000 paid; commitment fee of 2% of commitment amount in five quarterly installments.
Advance subject to filing and effectiveness of registration statement with the SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.